NCT03682120View on ClinicalTrials.gov

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

PHASE2CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Avian InfluenzaInfluenza Immunisation
Interventions
BIOLOGICAL

A/H7N9

"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."

DRUG

MF59

Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.

OTHER

Phosphate Buffered Saline (PBS) diluent

Diluent for Influenza Virus Vaccine.

Trial Locations (7)

35294-2050

University of Alabama at Birmingham School of Medicine - Alabama Vaccine Research Clinic, Birmingham

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

45229-3039

Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati

37232-0011

Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville

77555-5302

The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD), Galveston

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

98101-1466

Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03682120 - Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza | Biotech Hunter | Biotech Hunter